- Home
- MYGN vs MYN Comparison
MYGN vs MYN Comparison
Compare MYGN & MYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MYN
- Stock Information
- Founded
- MYGN 1991
- MYN 1992
- Country
- MYGN United States
- MYN United States
- Employees
- MYGN N/A
- MYN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MYN Finance Companies
- Sector
- MYGN Health Care
- MYN Finance
- Exchange
- MYGN Nasdaq
- MYN Nasdaq
- Market Cap
- MYGN 423.1M
- MYN 358.2M
- IPO Year
- MYGN 1995
- MYN N/A
- Fundamental
- Price
- MYGN $7.64
- MYN $9.88
- Analyst Decision
- MYGN Hold
- MYN
- Analyst Count
- MYGN 13
- MYN 0
- Target Price
- MYGN $13.50
- MYN N/A
- AVG Volume (30 Days)
- MYGN 1.4M
- MYN 86.0K
- Earning Date
- MYGN 11-06-2025
- MYN 01-01-0001
- Dividend Yield
- MYGN N/A
- MYN 4.12%
- EPS Growth
- MYGN N/A
- MYN N/A
- EPS
- MYGN N/A
- MYN N/A
- Revenue
- MYGN $832,900,000.00
- MYN N/A
- Revenue This Year
- MYGN $0.17
- MYN N/A
- Revenue Next Year
- MYGN $6.19
- MYN N/A
- P/E Ratio
- MYGN N/A
- MYN N/A
- Revenue Growth
- MYGN 3.83
- MYN N/A
- 52 Week Low
- MYGN $3.76
- MYN $8.47
- 52 Week High
- MYGN $29.30
- MYN $10.62
- Technical
- Relative Strength Index (RSI)
- MYGN 75.45
- MYN 80.29
- Support Level
- MYGN $6.73
- MYN $9.20
- Resistance Level
- MYGN $7.05
- MYN $9.33
- Average True Range (ATR)
- MYGN 0.38
- MYN 0.09
- MACD
- MYGN 0.10
- MYN 0.07
- Stochastic Oscillator
- MYGN 94.31
- MYN 97.89
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.